What question did this study set out to answer?

This analysis aims to evaluate the effectiveness of colchicine for preventing cardiovascular disease in people with diabetes.

March 29, 2026Diabetes and Vascular Disease Research0 citationsOpen Access

Colchicine For Cardiovascular Disease Prevention In Diabetics: A Meta-Analysis

Effect of colchicine for secondary prevention of cardiovascular diseases in individuals with diabetes: A meta-analysis of randomized trials

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis demonstrates colchicine reduces cardiovascular events in individuals with diabetes, indicating a potential preventive strategy.

This analysis aims to evaluate the effectiveness of colchicine for preventing cardiovascular disease in people with diabetes.
Conducted a systematic review of randomized controlled trials on colchicine and cardiovascular outcomes.
Analyzed data using a fixed-effects inverse-variance model in RevMan 5.4.
Included five RCTs with a total of 2977 participants, equally divided between colchicine and placebo.
Colchicine reduced major adverse cardiovascular events (MACE) significantly, HR 0.79 (95% CI 0.67-0.94, p = 0.006).
In diabetic participants, the effect was even stronger, HR 0.75 (95% CI 0.67-0.83, p < 0.001).
No increase in adverse events, with composites RR 0.81 (95% CI 0.68-0.96; p = 0.02).

Yasaratna et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

March 29, 2026Diabetes and Vascular Disease Research0 citationsOpen Access

Effect of colchicine for secondary prevention of cardiovascular diseases in individuals with diabetes: A meta-analysis of randomized trials

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis demonstrates colchicine reduces cardiovascular events in individuals with diabetes, indicating a potential preventive strategy.

This analysis aims to evaluate the effectiveness of colchicine for preventing cardiovascular disease in people with diabetes.
Conducted a systematic review of randomized controlled trials on colchicine and cardiovascular outcomes.
Analyzed data using a fixed-effects inverse-variance model in RevMan 5.4.
Included five RCTs with a total of 2977 participants, equally divided between colchicine and placebo.
Colchicine reduced major adverse cardiovascular events (MACE) significantly, HR 0.79 (95% CI 0.67-0.94, p = 0.006).
In diabetic participants, the effect was even stronger, HR 0.75 (95% CI 0.67-0.83, p < 0.001).
No increase in adverse events, with composites RR 0.81 (95% CI 0.68-0.96; p = 0.02).

Yasaratna et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark